Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
作者:Gui-Bai Liang、Xiaoxia Qian、Dennis Feng、Tesfaye Biftu、George Eiermann、Huaibing He、Barbara Leiting、Kathy Lyons、Aleksandr Petrov、Ranabir Sinha-Roy、Bei Zhang、Joseph Wu、Xiaoping Zhang、Nancy A. Thornberry、Ann E. Weber
DOI:10.1016/j.bmcl.2007.01.039
日期:2007.4
Following the discovery of N-acyl-1,4-diazepan-2-one as a novel pharmacophore for potent and selective DPP-4 inhibitors, optimization of this new lead with different substitution on the seven-membered ring resulted in several highly potent and selective, orally bioavailable, and efficacious DPP-4 inhibitors, such as 3R-methyl-1-cyclopropyl-1,4-diazepan-2-one derivative 9i (DPP-4 IC(50)=8.0 nM) and 3R,6R-dimethyl-1
在发现N-酰基-1,4-二氮杂-2-酮作为有效和选择性DPP-4抑制剂的新型药效团后,对这种新的先导物进行了优化,在七元环上进行了不同的取代,从而产生了数个高效且高效的DPP-4抑制剂。选择性,口服可生物利用且有效的DPP-4抑制剂,例如3R-甲基-1-环丙基-1,4-二氮杂-2-酮衍生物9i(DPP-4 IC(50)= 8.0 nM)和3R,6R-二甲基-1,4-二氮杂-2-酮衍生物14a(DPP-4 IC(50)= 9.7 nM)。